Table 3 Summary of Preclinical Efficacy of Group III mGlu Receptor Ligands
From: Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
Positive Symptom Models | Negative Symptom Models | Cognition Models | |
|---|---|---|---|
Group III agonist | |||
ACPT-I | Reduced NMDAR-HL and AHL [190] Reduced DOI-induced head twitches [190] | ||
mGlu 4 agonists | |||
LSP1-2111 | Reduced NMDAR-HL and AHL [191] Reduced DOI-induced head twitches [191] | ||
LSP4-2022 | Reduced NMDAR-HL [192] Reduced DOI-induced head twitches [192] | Reduced MK-801-induced deficits in social interaction [192] | Reduced MK-801-induced deficits in NOR [192] |
mGlu 4 PAMs | |||
Lu AF21934 | Reduced MK-801-induced deficits in social interaction [196, 238] | Rescued MK-801-induced deficits in the delayed spatial alternation task [196] Reduced MK-801-induced deficits in NOR [238] | |
Lu AF32615 | Reduced NMDAR-HL and AHL [196] Reduced DOI-induced head twitches [196] | Reduced MK-801-induced deficits in social interaction [196] | Rescued MK-801-induced deficits in the delayed spatial alternation task [196] |
ADX88178 | Reduced NMDAR-HL [197] Reduced DOI-induced head twitches [197] | Reduced immobility in FST [197] | |
mGlu 7 agonist | |||
AMN082 | Exacerbated NMDAR-HL [191] No effect on AHL [191] Exacerbated DOI-induced head twitches [191] | ||
mGlu 8 agonist | |||
(S)-3,4-DCPG | No effect on NMDAR-HL or AHL [221] | ||